Anavex Life Sciences Corp (AVXL)

[B60611]

Anavex/Missling cannot blame the ludicrous Alzheimer's TLD prediction on the CRO. If we take the PR literally (as we should be able to), by mid-2022 means before July 1. A 500+ person trial ending in mid-May is not reading out 6 weeks later. It's not a big mistake in and of itself, as no one will rely on that 1 line from a PR a year before the trial completes, but it's a dumb mistake, and it's quintessential Missling. The professional, competent CEO, whom seeks not to overpromise/underdeliver talks generally to start with and then adds more specificity as things become clearer. For example, "TLD is expected in 2022," a prediction which should be easy enough to meet, and then as things get closer Missling can give more details regarding timing.